I captured her spotify transcript if anyone want to read

New Post Public Reply Private Reply Replies (1) Message Board
twinter11
198
I captured her spotify transcript if anyone want to read it.

summary:

KEY HIGHLIGHTS: DR. LAUREN WILCOXEN ON BIOTECH BUILDERS (AUG 5, 2025)

Built for Lean, Virtual Biotechs: At Checkpoint Therapeutics, Dr. Wilcoxen led Regulatory Affairs, Clinical, CMC, and Supply Chain ("essentially most of operations" inside a flat, remote 24-person company with a 2-person regulatory team—relying on specialized external partners for manufacturing, bioanalytics, and clinical execution rather than bloated internal overhead.

Turned Single-Arm Early Data Into an Aligned FDA Filing: She guided Checkpoint's Phase 1 cutaneous squamous cell carcinoma dataset into an aligned FDA marketing application strategy, passing all sponsor and clinical inspections with zero efficacy or safety holdups.

Resolved an External CMO Complete Response Letter in Under a Year: When Checkpoint received a CRL in December 2023 due to Form 483 observations at its third-party contract manufacturer , she partnered directly with the manufacturer to remediate the issues, aligned with the FDA on the fix, resubmitted in June 2024, and won full FDA approval on December 13, 2024 with zero team turnover.

Aligned Leadership Early on Commercialization vs. Acquisition: She stresses that lean biotechs must align early on their endgame—avoiding costly internal manufacturing builds when the goal is securing FDA approval and executing competitive partnering or M&A discussions (which led directly to Checkpoint's acquisition by Sun Pharma).

Direct Continuity at CytoDyn: Having spent the past year advising CytoDyn on CLOVER and its oncology strategy before stepping into the COO and Head of Regulatory Affairs seat on November 20, 2026, she brings direct, battle-tested FDA Oncology CMC experience into CytoDyn's upcoming filings.

interview:

COMPLETE TRANSCRIPT: DR. LAUREN WILCOXEN ON BIOTECH BUILDERS (AUG 5, 2025)

Discovering Biotech Builders: An Introduction to Lauren Wilcoxen

Katie Barber (Host): Welcome to the Biotech Builders podcast, which features the stories, strategies, and insights from biotech industry experts. I'm Katie Barber, your host and co-founder of this podcast season. I'm a specialist biotech recruiter working at CT19, and I've spent most of my career building startup and scale-up biotechs. I'm looking forward to sharing a series of episodes from experts in R&D right through to HR and talent acquisition. You can follow CT19 on LinkedIn for all of our guest announcements.

Hello and welcome back to another episode of Biotech Builders, which is the podcast which dives into stories, strategies, and insights from experienced biotech industry leaders. Today I'm joined by the wonderful Lauren, who I've been fortunate to chat to many times in the last few years. Lauren is the Senior Vice President of Product Development and Regulatory Affairs for Checkpoint Therapeutics. They are a US-based biotech specializing in development and commercialization of immunotherapy and targeted oncology treatments for solid tumor cancers. Lauren and the Checkpoint team operate with a lean team of only 20 to 30 employees who I believe work remotely across the US, and it's been recently announced that Sun Pharma are planning to acquire Checkpoint. So today we'll hear from Lauren on her career to date, her recent journey at Checkpoint—which also includes a complete response letter from the FDA—and her advice for others working in the leadership of startup biotech. So Lauren, thank you so much for your time today. Would you do the honors of telling our listeners a little bit more about you?

Lauren's Unconventional Path to Regulatory Affairs Leadership

Dr. Lauren Wilcoxen: Sure, I'd be happy to. Thank you so much for having me. So, yeah, it's interesting thinking back through my career and how it's taken me here. Originally, when I was quite young, I thought I would be a veterinarian and then a physician, and then got the science bug in college and decided I wanted to pursue a career as a scientist. So I went and got my PhD—scientist by training. And I think towards the end of graduate school I was a bit burnt out of working at the bench and decided that wasn't a career for me, and wanted to kind of go back to where I started, which was being closer to patients and having that aspect in terms of medicine in my life. And so that really drew me to clinical research, which frankly, regulatory affairs was a happy accident. But I'm glad that I found it because you get to be exposed to every aspect of drug development, from early-stage molecules all the way to commercialization and treatment of patients.

So I am, as you mentioned, Head of Product Development and Regulatory Affairs at Checkpoint Therapeutics. In that role, I lead the regulatory affairs department as well as clinical, CMC, and supply chain functions for the company. So essentially most of operations is where those regulatory affairs strategies sit. I am in regulatory affairs, a team of two—so I have one other team member in regulatory affairs. Across the company, we actually have 24 employees. So we're quite small and nimble. Most of the work that we do is outsourced to partners that we work with—vendors, bioanalytical vendors, manufacturing vendors. So that allows us to keep our team quite small. And yeah, it's been quite the journey. I love what I do. I'm lucky to love what I do, and I'm happy to talk.

Katie Barber (Host): Amazing. Well, thank you so much for giving us your time to inspire other people within our industry, I'm sure particularly within regulatory affairs. It's actually not the first time someone's told me that their career in regulatory has been a bit of a happy accident. Can you tell us a little bit more about how that panned out for you? How did you stumble across that as a profession?

Dr. Lauren Wilcoxen: Sure, sure. So as I mentioned, towards the end of graduate school, I was pretty sure I didn't want a career at the bench. I wanted a career that was more translational and closer to the clinic and being able to realize therapies and see the impact of what I did. The work that I was doing in graduate school, while not necessarily true basic science—there was a translational aspect to it—I was working with human viruses leading to potential vaccine development, but it was still probably at least a decade to decades from actually having realization in the clinic. And so that was really what drew me to clinical research.

I started doing some informational interviews in graduate school, meeting with prospective industry leaders and even folks that were earlier in their careers. And I was trying to understand: how do you make that shift from academia to industry? What interests me? Where can I use my strengths in academia as a scientist and translate those to industry? So that was quite helpful, also working with the graduate school professional development group in getting my CV ready, and again, how do I translate these skills into something that might be useful and might get picked up by HR?

And so eventually I went to a career fair that was specifically aimed at PhD and Master's scientists locally. And at that career fair, the day before, I was scanning the companies that were going to be there, and one of the companies on the list was Rho. Rho is a clinical research organization local to where I am here in North Carolina. And I saw that they had this opportunity as an Integrated Product Development Associate at Rho, and that was specifically for PhD-level scientists to come in and learn essentially clinical research and regulatory affairs from the get-go. And so that seemed like a potentially good option for me.

So I went to the career fair the next day. I brought a copy of my CV and stood in line actually to speak to the HR representative there at the table, and basically was totally uncomfortable doing this, but I did it anyway and got up the courage to give her my CV and sort of do my quick elevator pitch for this particular position. And she was taking notes on my CV actually while I was talking. And then probably less than a week later, I got a phone call for my first interview there. And that was it. I just had several interviews there all the way up through the co-CEOs at the time, and then got an offer for a job in February of that year. And I had to remind them that I still had to defend my PhD in April of that year. And they said, "Okay, that's great, we'll hold your position for you."

So that was pretty much it. When I got into it, I thought, "Okay, I'm sort of familiar with it, but not completely." And it was a great program because they had not only on-the-job training, mentoring, and shadowing, but they actually formally gave you a mentor to work with—someone who was familiar with the program. And then we also had coursework as part of our training there, and after about a year or so, that converted to a full-time position essentially as well at the company. And so it was an incredible opportunity. It doesn't come along that often, because I still speak to a lot of graduate students and postdocs who are trying to figure out: how do I make that jump? How do I transition? How do I talk the language of industry professionals and get that opportunity? And I was lucky, and obviously I did my research, I did my preparation, but I also found a position that was uniquely positioned to help me with that transition.

Katie Barber (Host): Yeah, absolutely. And I don't see as many of those entry-level positions around now as we used to, which is a real shame. And I agree with you, I think it's definitely hard now for a...

Leadership Goals, Networking, and Risk Tolerance in Startup Biotech

Dr. Lauren Wilcoxen: ...and everything in between. I think it's important to have goals when you're in a small company. Maybe you have an end goal of commercialization and commercializing yourself. Maybe your end goal is to be acquired. Maybe there's different kinds of goals that you have as a small company. Being comfortable with that as well—trying to be on the same page with what those goals are in leadership early on—is also important.

I think something that helped me, and I encourage folks that I talk to earlier in their careers or who are trying to make a career transition, is: take advantage of LinkedIn, take advantage of local networking organizations or local professional organizations. There's a local one here in North Carolina for regulatory affairs that helped me network, helped me meet new people, exposed me to different types of positions and different areas in the industry that I hadn't really thought about before. And I think that can be incredibly helpful if you are looking to enter into that phase, or maybe you're at a big company and you're like, "Well, what's it like as a startup?"

The best way is to ask questions. Very early in my career I was very uncomfortable with that—was not the person to go to those environments and conferences and networking events and really want to network. I would always think, "I don't know if I should talk to this person, and what do I say? I don't want to interrupt this group, and how do I start a conversation? This is so awkward, right?" And you just have to sort of be comfortable with being uncomfortable—go ahead and do it anyway and have the conversation. And they're probably feeling something similar to where you are, or maybe they did early on in their career and they understand, right? So at least sort of rip the band-aid off and try and have the conversation, and you never know where it'll lead.

So many of those conversations have led to friendships, have led to mentorships, have led to professional connections who maybe were one or two degrees removed from somebody else who I learned from or benefited from professionally. So I think again, be comfortable with being uncomfortable. Ask questions, talk to people in the position or in a company like one that you would like to work at to really try to peel back those layers—understand what you're getting into and understand the level of risk. If you're risk-intolerant, a startup environment is probably not for you, and that's okay, right? We all have different values. We all have different tolerances for risk, and so I think trying to understand that about yourself is really helpful, and some of these conversations can help with that as well.

Checkpoint Therapeutics' Resilient Path to FDA Approval

Katie Barber (Host): Thank you for sharing that. There was loads of advice there and I think that's going to be super helpful to a lot of people who are sort of thinking about startup biotech. I think the first thing that comes to a lot of people's mind is risk. And if that's maybe not the right time for you to take a risk, that's fine too, right? Startup biotech has so much innovation—it could be the right time for you later down the line. And one sort of topic of conversation I was really keen to talk to you about more today is your recent success at Checkpoint, because it's obviously been a really interesting story. You had a complete response letter from the FDA, which obviously then you and your team were able to turn around. You've had a recent filing and now an acquisition as well. Can you tell us a little bit more about what you've been working on, how it's all unraveled in the last 12 months or so?

Dr. Lauren Wilcoxen: Yes, it's been quite the journey. So as I mentioned, when I joined Checkpoint, they had gotten some really great pivotal data from a Phase 1 study in cutaneous squamous cell carcinoma patients where, based on those data, they knew that they had met—sort of early exceeded—the minimum requirements for potential approvability in that product, based on safety and efficacy. And so they knew that they wanted to file a marketing application.

We worked through what that strategy looked like, how to prepare the application, what we needed to do in order to be able to negotiate our strategy with FDA. So those meetings with FDA went well. We felt like we aligned on the strategy. We submitted the marketing application in January of 2023. In terms of going through the review process—going through our sponsor inspection, the clinical inspections—everything went incredibly well. We really didn't have any holdups from FDA in terms of clinical data or other issues, but we ended up getting some FDA observations—Form 483—for an external manufacturer who had some things that needed to be worked through essentially as part of our application, and who impacted our application that led to the Complete Response Letter from FDA.

It was pretty specific in terms of what they wanted us to do to be able to remediate the application, but it required us partnering with our manufacturing organization to remediate those issues. So once we got the Complete Response Letter—that was in December of 2023, right before Christmas—it was tough. It was tough to give that news to our team and to the rest of our community who had really been looking forward to the approval of the product. And we had to come back together as a team and say: first of all, are these things that we can overcome? Can we figure out a way to get this done quickly? Because again, as a small company, you have limited capital, you have to make choices—can we do this? How much time is it going to take? And is it something that we can overcome?

So, yeah, as you mentioned, in terms of our ability to come together as a team and persevere—saying, "Yes, we have a goal and we will make this happen"—is incredible. It's rare to have the level of teamwork that we have and continuity, as you mentioned, in a completely virtual remote environment nonetheless too, right? But yeah, we were able to say, "Yeah, we can do this, let's make this happen," figure out a way, worked with our manufacturing partner to remediate the issues as it applied to our application, and also get ready for resubmitting our marketing application.

We met with FDA to talk through what we had done and make sure that we were on the same page and aligned on that strategy. And then we resubmitted the application in June of 2024 last year. And then we got approval on December 13th—Friday the 13th of last year, 2024—which again was so interesting because it was about a year, just under a year, from the Complete Response Letter that we got the approval. And so this sort of rush of emotions comes over you, and immediately I just wanted to share the news with my team. We all got on the phone, and that was like the best sort of early holiday present, right? Just totally different ends of the spectrum.

And yeah, the unique thing too is that between the Complete Response Letter and the resubmission and even today, none of our employees left. Everybody stuck together to make it happen, which has just been an incredible accomplishment to get to that point. And I'm so proud of our team and the community to really come together on this and make this happen for our patients.

Katie Barber (Host): As a leader, how did you motivate your team in such a tough time? Like you said, just before the holidays, finding out that you've got that letter and then all the work that you guys are going to have to go into to try and overcome it—how did you motivate your team in that time?

Dr. Lauren Wilcoxen: Yeah, I think I'm a very transparent leader and team member and colleague. I don't want to understate the reality... But there are times when you know, if you need to be at something for your kids or your parents, and you have to fit that into your schedule, well, then you can work later and you can work earlier and you can kind of work around those things—because life happens, right? I think when you're commuting into an office—at one time I was driving an hour and a half each way to work—that takes up so much of your time, and trying to figure out how do I get life done around those things makes things difficult to where people then can leave because they find something else that gives them more flexibility. So I think that helps a lot.

There's also just a level of how we have maintained the team and how we have operated where it is very much flat. We're so small that we often have one person who is the leader and the expert in a particular area—whether it's process development, whether it's regulatory, whether it's supply chain, we have one or maybe a handful of people that are doing that work. And so because of that, everybody comes to the table as an expert, everybody comes to the table as a stakeholder, everybody comes to the table with their ideas and with what we need to be able to get done in order to execute a strategy. I think that really helps because it isn't this sort of top-down approach where it's "my way or the highway" and "this is how it needs to be done." It's a collective discussion. It's a collective strategy where, yeah, ultimately we have to pick one strategy and come together on it and back it up. But often it's with a lot of conversation and it's very evidence-based and very logical where we come together and make that compromise with respect to the strategy going forward. Because of all of those reasons, I think that's really helped to bring us together again, build trust, build resilience—all of those things that are necessary for really any team culture, but in particular when you're remote, having that level of trust I think is really important.

Strategic Outsourcing for Agile and Lean Biotech Operations

Katie Barber (Host): I think being able to still connect with the person is so important even when you are remote. And I was also really keen to talk to you about the lean nature of your organization, right, because it's no secret you're a smaller business. Like you said, you have typically one person who's a subject matter expert in an area. How did you build the organization in the last few years? Who did you choose to outsource work to? What consultants did you rely on or partners? Can you give us a little bit of an insight into how you found it worked the best?

Dr. Lauren Wilcoxen: So when I joined the company, several of the key partnerships—for example, the manufacturing partnerships and other partnerships—were already established. Most of those, again, were done strategically. The company, as Checkpoint, wanted to stay small—wanted to really stay small and be focused on the subject matter experts that we needed in specific domains. The rest of the work was predominantly strategic outsourcing.

It was: is it more cost-effective to bring this internally, or is it better to outsource it to the folks that know what they're doing and they have established processes and they can do that work? And then it allows us, frankly, some agility as well to move around and make different choices. Certainly from a manufacturing perspective, we changed manufacturers over time as we grew, as we were preparing to be able to file a marketing application. But a lot of those lessons learned were done before I joined the company.

When I joined, it was a period of growth where the company had been predominantly a very, very small company—like 3 to 4 people—and then all of a sudden grew to 24 people. And so we were growing quickly. We were developing processes both literally in terms of SOPs, but also in terms of how we work together and plan and execute and all of those things. In terms of the rest of the outsourcing—and also being virtual—obviously it helps with overhead costs. We didn't have to have everybody necessarily coming into the office. We set up everybody at their homes. That gives them more flexibility. With respect to the other labs and things like that, again, those were the labs that had been used. Over time some of that had changed with growth as well, but those are the experts.

And so, I've been at other companies where you decided, "Okay, we're going to take the manufacturing in-house—long term, that's going to be the better strategy," or "we're going to take this analytical work in-house." And sometimes that makes sense if it is a longer-term strategy. For us, we knew that we were likely going to get to approval and then make a decision for commercialization, and we were going to have some level of partnership—either that was going to be outsourced, or potentially we were going to work with a partner or an acquiring company in order to take things forward. And so for us, bringing in manufacturing or lab work—all of those things didn't necessarily make sense for the ultimate strategy that we had, the end game for the company. I think that worked out for us. It doesn't work out for every company, but for the model that we were trying to establish with this particular model, it works. And again, I think it's more of: what's your end game, and ultimately are you kind of looking for the short-term or long-term strategy for the company and building that out? And for us it worked. It doesn't always work, or for us it worked quite well.

Navigating Commercialization and Strategic Biotech Acquisitions

Katie Barber (Host): And at the time we're recording this, obviously the news has broken of the Sun Pharma acquisition, which is super exciting for you to be able to commercialize now. And what advice do you have to other biotech leaders that might be in your position where you were a year ago gearing up for what commercialization looks like?

Dr. Lauren Wilcoxen: You know, I think one of the things that we had discussed early on was: do we take this on ourselves? Do we hire some key folks internally to help with the commercial launch, and then also partner with another company that specifically does this kind of work—like augment your team, for example, a contract research organization that has a commercial group sort of built in? That again is more of a strategic outsourcing play where it's augmenting your team and it's an extension of your team, but you're not necessarily having to hire a lot of people internally.

I think we wanted to be really smart. We had a lot of conversations internally with the leadership, with the board about what strategy makes the most sense for us—again, short term, long term, what are the costs associated with that if we do it ourselves (and that involves financing, how does that impact our investors, how does it impact our employees)? There were a lot of conversations along those lines, and we got very far down the line potentially with doing that strategic outsourcing partnership.

Once we got the Complete Response Letter from FDA, then again it was more of an "Okay, we need to sort of shift gears and now we have to go back and figure out: can we resubmit?" And once we resubmitted, that gave us even more time to reflect and also have conversations with companies about what are other models of partnership that we can explore—of course, one of which was acquisition. And so we had conversations with multiple companies. Ultimately we felt, and with discussions with the board, that this deal with Sun Pharma would likely be the best one for us in order to get the drug to patients...

Closing Remarks & Gratitude

Dr. Lauren Wilcoxen: ...Thank you for what you're doing. I think it's really, really important. It builds relationships and certainly has helped me build relationships with my team. But I also think that it's really important to do that, and things come full circle. You've got to give back and you've got to recognize where folks have helped you along the way as well.

Katie Barber (Host): It's been wonderful to hear about your journey—obviously your recent story from Checkpoint as well—and you've obviously had so much advice now for any listener to be able to take away. So thank you ever so much for joining us, and I'm sure that we're super excited to hear whatever is going to be next for you on your journey in biotech.

Dr. Lauren Wilcoxen: Thank you so much for having me.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 191

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 95

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 77

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 171

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 72

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 23

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Promising Industrials Stocks: AVAV, GMS, VRRM Insights

Updated Category News Views 190

Identifying Opportunities in the Industrials Sector In today's market, identifying oversold stocks in the industrials sector presents a golden opportunity for investors seeking undervalued assets. An oversold stock usually indicates that its price has dropped significantly, creating potential for future upward movement. Understanding the RSI Indicator The Relative...

Continue Reading
Florida Cancer Specialists Innovates Care with Navigation Program

Updated Category News Views 252

Florida Cancer Specialists Revolutionizes Oncology Navigation Florida Cancer Specialists & Research Institute, LLC (FCS) recently unveiled an intriguing case study that illustrates the profound impact of their patient navigation program. This initiative is structured under the Principal Illness Navigation (PIN) billing codes introduced by the Centers for Medicare &...

Continue Reading
Celebrating Creativity: ASCAP Composers' Choice Awards 2025

Updated Category News Views 267

ASCAP Honors Top Screen Composers for 2025 The American Society of Composers, Authors and Publishers (ASCAP) has recognized the incredible talent of top screen composers at the highly anticipated ASCAP Composers' Choice Awards for 2025. This event highlights the artists whose musical creations bring depth and emotion to films, TV series, and video games. The awards shine...

Continue Reading
Innovative Features of Catalogic's DPX vPlus Unveiled

Updated Category News Views 105

Enhancing Data Protection with DPX vPlus 7.0 Catalogic Software, a reputable provider of secure data protection solutions with over 25 years of experience, has recently launched an impressive upgrade to its enterprise data protection software: DPX vPlus 7.0. This new version is designed to meet the evolving needs of modern enterprise environments, offering significant...

Continue Reading
Legal Action Reminders for Investors in CAE, Inc.

Updated Category News Views 99

Investor Alert: Class Action Lawsuit Against CAE, Inc. ClaimsFiler is notifying investors about a significant legal case involving CAE, Inc. (NYSE: CAE). If you've experienced losses exceeding $100,000 from your investment in CAE, it's important to take action quickly to safeguard your rights. Overview of the Class Action Lawsuit This lawsuit claims that CAE and certain...

Continue Reading